Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - dexamethasone, quantity: 1 mg/ml - eye drops, suspension - excipient ingredients: dibasic sodium phosphate; polysorbate 80; disodium edetate; sodium chloride; benzalkonium chloride; purified water; hypromellose; citric acid monohydrate; sodium hydroxide - indications as at 16 jan 2005 : steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in oedema and inflammation; acute and chronic anterior uveitis; corneal injury from chemical radiation or thermal burns or penetration of foreign bodies.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - phenylephrine hydrochloride, quantity: 1.2 mg/ml; prednisolone acetate, quantity: 10 mg/ml - eye drops, suspension - excipient ingredients: benzalkonium chloride; sodium metabisulfite; sodium citrate dihydrate; sodium chloride; boric acid; hypromellose; disodium edetate; phenazone; polysorbate 80; purified water; hydrochloric acid; sodium hydroxide - severe inflammation (non-infectious) of the eye, such as acute iritis, iridocyclitis, scleritis, episcleritis, uveitis, resistant ocular allergy and inflammation following surgery (where no infectious aetiology is suspected), particularly where unusually rapid control of the inflammation is required.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 10 mg/ml - injection, suspension - excipient ingredients: carmellose sodium; polysorbate 80; benzyl alcohol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intra-articular: kenacort-a 10 injection (sterile triamcinolone acetonide suspension usp) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute non-specific tenosynovitis, post-traumatic osteoarthritis. intradermal: intralesional administration of kenacort-a 10 injection is indicated for the treatment of keloids, discoid lupus erythermatous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus ( neurodermatitis), kenacort-a 10 injection also may be useful in cystic tumours of an aponeurosis or tendon ( ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg/g - cream - excipient ingredients: sodium hydroxide; stearyl alcohol; lactic acid; cetyl esters wax; purified water; chlorhexidine hydrochloride; sorbitan monostearate; octyldodecanol; glycerol; polysorbate 60; cetyl alcohol - indications as at 18 december 2001. vulvo-vaginal complaints due to oestrogen deficiency associated with the climacteric and the postmenopause or after ovariectomy: atrophic vaginitis. puritis vulvae. dyspareunia due to vulvo-vaginal atrophy. as auxiliary therapy in the treatment of vaginal infections. as pre-operative therapy for vulvo-vaginal surgery and during subsequent convalescence. ulcers in the case of prolapse of the uterus or vagina. to avoid misinterpretation of a cytological smear.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propyl hydroxybenzoate; polysorbate 60; white soft paraffin; purified water; propylene glycol; stearyl alcohol - indications as at 30 july 1990: solar and senile keratoses, bowen's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; hydrochloric acid; sodium hydroxide - indications as at 5 october 2000: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sulfamethoxazole, quantity: 32.922 mg/g; trimethoprim, quantity: 6.584 mg/g - oral liquid, suspension - excipient ingredients: methyl hydroxybenzoate; sodium benzoate; carmellose sodium; sorbitol; dispersible cellulose; glycerol; polysorbate 80; ethanol; sunset yellow fcf; allura red ac; saccharin sodium; citric acid; purified water; flavour - indications as at 01 march 2002 : upper and lower respiratory tract infections; renal and urinary tract infections; genital tract infections; gastrointestinal tract infections; skin and wound infections; septicaemias, and other infections caused by sensitive organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; anise oil; polysorbate 80; saccharin; purified water - gastrografin is a contrast medium for examination of the gastrointestinal tract. it can be administered orally and as enema and is primarily indicated in cases in which the use barium sulfate is unsatisfactory, undesirable or contraindicated. among these are: - suspected partial or complete stenosis - acute haemorrhage - threatening perforation (peptic ulcer, diverticulum) - other acute conditions which are likely to require surgery - after resection of the stomach or the intestine (danger of perforation or leak) - megacolon - visualisation of a foreign body or tumour before endoscopy - visualisation of gastrointestinal fistula. in addition to these conditions gastrografin can generally be used for the same purposes as barium sulfate with the exception of the visualisation of mucosal diseases. due to the insufficient coating properties of gastrografin, barium sulfate should be used for single or double contrast techniques. in combination with barium sulfate, gastrografin has considerably improved routine inve

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - alteplase 10mg - injection with diluent - 10 mg - active: alteplase 10mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - alteplase 20mg - injection with diluent - 20 mg - active: alteplase 20mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.